COMP <GO>
TWST vs NBIX // PIOTROSKI F-SCORE QUALITY
Twist Bioscience Corporation (NASDAQ) VS. Neurocrine Biosciences Inc. (NASDAQ) • 15-METRIC TALLY: TWST 3
— NBIX 9
▲ PIOTROSKI F-SCORE QUALITY LEADER: NBIX
LAST: $173.45 (0.00%) • MKT CAP: $11.50B
piotroski-score
6/9
LAST: $146.38 (+0.58%) • MKT CAP: $14.88B
piotroski-score
9/9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TWST VS. NBIX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TWST | NBIX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 94.20% | 96.00% | -1.80 | NBIX | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -11.70% | 15.70% | -27.40 | NBIX | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 22.8x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -0.66% | 5.03% | -5.69 | NBIX | /fcf-yield <GO> |
| Operating Margin | -4.20% | 21.60% | -25.80 | NBIX | /operating-margins <GO> |
| Net Profit Margin | -2.40% | 16.70% | -19.10 | NBIX | /net-margins <GO> |
| Revenue Growth (YoY) | 16.50% | 21.40% | -4.90 | NBIX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 8.13 | +17.87 | TWST | /balance-sheet <GO> |
| Piotroski F-Score Quality ACTIVE | 6/9 | 9/9 | -3.00 | NBIX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 57.2 | 56.1 | +1.10 | TWST | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.98 | 1.13 | -0.15 | NBIX | /macro-sensitivity <GO> |
| Forward P/E Multiple | 21.0x | 26.1x | -5.10 | TWST | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $11.50B | $14.88B | -$3.38B | NBIX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TWST REV | NBIX REV | TWST GROSS % | NBIX GROSS % | TWST FCF | NBIX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $2.86B | — | 98.2% | -$75.6M | $748.7M |
| FY 2024 | $0 | $2.36B | — | 98.6% | -$69.2M | $557.2M |
| FY 2023 | $0 | $1.89B | — | — | -$142.5M | $305.0M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TWST // BETA 0.98
NBIX // BETA 1.13